Education
About Us
Working with TipRanks
Follow Us
Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
Total Valuation
Prescient Therapeutics Limited has a market cap or net worth of AU$44.16M. The enterprise value is AU$28.51M.
Market CapAU$44.16M
Enterprise ValueAU$28.51M
Share Statistics
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,051,514,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Prescient Therapeutics Limited’s return on equity (ROE) is -0.64 and return on invested capital (ROIC) is -26.77%.
Return on Equity (ROE)-0.64
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-26.77%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee1.45M
Profits Per Employee0.00
Employee Count3
Asset Turnover0.30
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Prescient Therapeutics Limited is ―. Prescient Therapeutics Limited’s PEG ratio is 0.45.
PE Ratio―
PS Ratio8.13
PB Ratio3.11
Price to Fair Value3.11
Price to FCF-4.89
Price to Operating Cash Flow-3.49
PEG Ratio0.45
Income Statement
In the last 12 months, Prescient Therapeutics Limited had revenue of 4.36M and earned -7.32M in profits. Earnings per share was -0.01.
Revenue4.36M
Gross Profit4.36M
Operating Income-7.54M
Pretax Income-7.32M
Net Income-7.32M
EBITDA-7.54M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -7.24M and capital expenditures 4.00, giving a free cash flow of -7.24M billion.
Operating Cash Flow-7.24M
Free Cash Flow-7.24M
Free Cash Flow per Share>-0.01
Dividends & Yields
Prescient Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.68
52-Week Price Change25.00%
50-Day Moving Average0.04
200-Day Moving Average0.04
Relative Strength Index (RSI)94.33
Average Volume (3m)690.15K
Important Dates
Prescient Therapeutics Limited upcoming earnings date is Feb 20, 2026, TBA (Not Confirmed).
Last Earnings DateAug 20, 2025
Next Earnings DateFeb 20, 2026
Ex-Dividend Date―
Financial Position
Prescient Therapeutics Limited as a current ratio of 4.08, with Debt / Equity ratio of 0.22%
Current Ratio4.08
Quick Ratio4.08
Debt to Market Cap0.00
Net Debt to EBITDA0.92
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Prescient Therapeutics Limited has paid -4.36M in taxes.
Income Tax-4.36M
Effective Tax Rate0.59
Enterprise Valuation
Prescient Therapeutics Limited EV to EBITDA ratio is -3.78, with an EV/FCF ratio of -3.93.
EV to Sales6.54
EV to EBITDA-3.78
EV to Free Cash Flow-3.93
EV to Operating Cash Flow-3.93
Balance Sheet
Prescient Therapeutics Limited has AU$6.93M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$6.93M billion.
Cash & Marketable SecuritiesAU$6.93M
Total DebtAU$0.00
Net CashAU$6.93M
Net Cash Per Share<AU$0.01
Tangible Book Value Per ShareAU$0.01
Margins
Gross margin is 100.00%, with operating margin of -172.98%, and net profit margin of -168.09%.
Gross Margin100.00%
Operating Margin-172.98%
Pretax Margin-168.09%
Net Profit Margin-168.09%
EBITDA Margin-172.96%
EBIT Margin-172.98%
Analyst Forecast
The average price target for Prescient Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast10.78%